Reverse Merger Success: Making It Out Of The Micro-Caps
Only about one-quarter of reverse mergers in recent years have market caps of more than $250 million. Of these, only about nine have become substantial companies since the reverse merger. Those that made it work say terrific assets, a track record of success and a strong management team are key to success.
You may also be interested in...
Momentum builds for Pharmacyclics/J&J’s ibrutinib with release of new data at the American Society of Hematology meeting, suggesting the drug has a shot at accelerated approval in sub-populations with high unmet need and potential in a range of B-cell cancers. Profiles of competitors from Gilead and Infinity/Takeda also came into greater focus at ASH.
While public, regulatory and law enforcement attitudes toward marijuana in the U.S. continue to shift, it’s still tough to pursue legitimate clinical research on cannabis and cannabinoids. Could the exceptions slowly become the rule?
An estimated 400 million people globally are infected with hepatitis B, which can result in liver cancer and cirrhosis. Recent advances in RNA and other technologies may provide movement toward a cure, but it’s not clear yet if the biopharma industry will find the economics motivating enough for an all-out effort.